België - Frans - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - valsartan 80 mg; bésilate d'amlodipine - eq. amlodipine 5 mg - comprimé pelliculé - valsartan and amlodipine

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinome, poumon non à petites cellules - agents antinéoplasiques - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

België - Frans - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - valsartan 160 mg; bésilate d'amlodipine - eq. amlodipine 10 mg - comprimé pelliculé - valsartan and amlodipine

België - Frans - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - valsartan 160 mg; bésilate d'amlodipine - eq. amlodipine 5 mg - comprimé pelliculé - valsartan and amlodipine

België - Frans - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - valsartan 80 mg; bésilate d'amlodipine - eq. amlodipine 5 mg - comprimé pelliculé - valsartan and amlodipine

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - imagerie des radionucléides - produits radiopharmaceutiques de diagnostic - ce médicament est destiné à un usage diagnostique uniquement. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - bénigne de la prostate tumeurs, résistant À la castration - produits radiopharmaceutiques thérapeutiques - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Canada - Frans - Health Canada

bausch health, canada inc. - clonazépam - comprimé - 0.5mg - clonazépam 0.5mg - benzodiazepines

Canada - Frans - Health Canada

bausch health, canada inc. - clonazépam - comprimé - 1mg - clonazépam 1mg - benzodiazepines

Canada - Frans - Health Canada

bausch health, canada inc. - clonazépam - comprimé - 2mg - clonazépam 2mg - benzodiazepines